Gilead's Ambition: To Help End the HIV Epidemic
- 28
NORTHAMPTON, MA / ACCESSWIRE / November 28, 2023 / "At Gilead, we have a bold ambition: We'd like to help end the HIV epidemic for everyone, everywhere and we know you cannot do that alone," shared Janet Dorling, Senior Vice President, Intercontinental Region and Global Patient Solutions.
Through our community partnerships in low- and middle-income countries, we are working together to expand access and reduce barriers to care while embracing innovation.
The panel discussion at the recent World Health Summit also featured leaders from The Global Network of People Living with HIV (GNP+), UNAIDS and PEPFAR.
Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Originally published by Gilead Sciences
View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.
Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: [email protected]
SOURCE: Gilead Sciences
View source version on accesswire.com:
https://www.accesswire.com/810733/gileads-ambition-to-help-end-the-hiv-epidemic
ACCESSWIRE is a premier news and communications network, providing regional, national, and global news to hundreds of clients globally. In addition to our world class and ever growing distribution network, ACCESSWIRE is also leading the way in social engagement, targeting and analytics.
